Telomir Pharmaceuticals reported on January 5, 2026, that its drug Telomir-1 significantly reduced tumor growth in aggressive triple-negative breast cancer models, showing promise for patient selection in clinical trials.
AI Assistant
TELOMIR PHARMACEUTICALS INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.